Clinical utility of a bayesian dosing program for phenytoin

M. D. Privitera, R. W. Homan, T. M. Ludden, C. C. Peck, Michael Vasko

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

We performed two studies to assess the clinical utility of a Bayesian regression analysis computer program for phenytoin (PHT). In a randomized prospective study of 40 epileptic patients, the dosing program was significantly more accurate (p = 0.002) and less biased (p = 0.02) than a group of physicians at hitting a target PHT serum-concentration. Initial serum PHT concentrations that were not steady state were associated with the largest dosing errors by physicians but did not affect the accuracy of the dosing program. In a second study, we used the dosing program to predict 91 serum concentrations in 31 patients with PHT toxicity after the drug was stopped (initial concentration 26-69 μg/ml). The program predicted serum concentrations with a mean error of 3.49 ± 0.29 μg/ml without significant tendency to overor underpredict. We conclude that this dosing program may aid clinicians by improving dosing accuracy and predicting serum concentrations in patients with PHT toxicity.

Original languageEnglish (US)
Pages (from-to)285-294
Number of pages10
JournalTherapeutic Drug Monitoring
Volume11
Issue number3
StatePublished - 1989
Externally publishedYes

Fingerprint

Phenytoin
Serum
Toxicity
Physicians
Bayes Theorem
Drug-Related Side Effects and Adverse Reactions
Regression analysis
Computer program listings
Software
Regression Analysis
Prospective Studies
Pharmaceutical Preparations

Keywords

  • Computer
  • Pharmacoinetics
  • Phenytoin
  • Toxicity

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Health, Toxicology and Mutagenesis
  • Public Health, Environmental and Occupational Health
  • Toxicology

Cite this

Privitera, M. D., Homan, R. W., Ludden, T. M., Peck, C. C., & Vasko, M. (1989). Clinical utility of a bayesian dosing program for phenytoin. Therapeutic Drug Monitoring, 11(3), 285-294.

Clinical utility of a bayesian dosing program for phenytoin. / Privitera, M. D.; Homan, R. W.; Ludden, T. M.; Peck, C. C.; Vasko, Michael.

In: Therapeutic Drug Monitoring, Vol. 11, No. 3, 1989, p. 285-294.

Research output: Contribution to journalArticle

Privitera, MD, Homan, RW, Ludden, TM, Peck, CC & Vasko, M 1989, 'Clinical utility of a bayesian dosing program for phenytoin', Therapeutic Drug Monitoring, vol. 11, no. 3, pp. 285-294.
Privitera MD, Homan RW, Ludden TM, Peck CC, Vasko M. Clinical utility of a bayesian dosing program for phenytoin. Therapeutic Drug Monitoring. 1989;11(3):285-294.
Privitera, M. D. ; Homan, R. W. ; Ludden, T. M. ; Peck, C. C. ; Vasko, Michael. / Clinical utility of a bayesian dosing program for phenytoin. In: Therapeutic Drug Monitoring. 1989 ; Vol. 11, No. 3. pp. 285-294.
@article{2438ddbd4e1c47e8a3345212b5cd9c52,
title = "Clinical utility of a bayesian dosing program for phenytoin",
abstract = "We performed two studies to assess the clinical utility of a Bayesian regression analysis computer program for phenytoin (PHT). In a randomized prospective study of 40 epileptic patients, the dosing program was significantly more accurate (p = 0.002) and less biased (p = 0.02) than a group of physicians at hitting a target PHT serum-concentration. Initial serum PHT concentrations that were not steady state were associated with the largest dosing errors by physicians but did not affect the accuracy of the dosing program. In a second study, we used the dosing program to predict 91 serum concentrations in 31 patients with PHT toxicity after the drug was stopped (initial concentration 26-69 μg/ml). The program predicted serum concentrations with a mean error of 3.49 ± 0.29 μg/ml without significant tendency to overor underpredict. We conclude that this dosing program may aid clinicians by improving dosing accuracy and predicting serum concentrations in patients with PHT toxicity.",
keywords = "Computer, Pharmacoinetics, Phenytoin, Toxicity",
author = "Privitera, {M. D.} and Homan, {R. W.} and Ludden, {T. M.} and Peck, {C. C.} and Michael Vasko",
year = "1989",
language = "English (US)",
volume = "11",
pages = "285--294",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Clinical utility of a bayesian dosing program for phenytoin

AU - Privitera, M. D.

AU - Homan, R. W.

AU - Ludden, T. M.

AU - Peck, C. C.

AU - Vasko, Michael

PY - 1989

Y1 - 1989

N2 - We performed two studies to assess the clinical utility of a Bayesian regression analysis computer program for phenytoin (PHT). In a randomized prospective study of 40 epileptic patients, the dosing program was significantly more accurate (p = 0.002) and less biased (p = 0.02) than a group of physicians at hitting a target PHT serum-concentration. Initial serum PHT concentrations that were not steady state were associated with the largest dosing errors by physicians but did not affect the accuracy of the dosing program. In a second study, we used the dosing program to predict 91 serum concentrations in 31 patients with PHT toxicity after the drug was stopped (initial concentration 26-69 μg/ml). The program predicted serum concentrations with a mean error of 3.49 ± 0.29 μg/ml without significant tendency to overor underpredict. We conclude that this dosing program may aid clinicians by improving dosing accuracy and predicting serum concentrations in patients with PHT toxicity.

AB - We performed two studies to assess the clinical utility of a Bayesian regression analysis computer program for phenytoin (PHT). In a randomized prospective study of 40 epileptic patients, the dosing program was significantly more accurate (p = 0.002) and less biased (p = 0.02) than a group of physicians at hitting a target PHT serum-concentration. Initial serum PHT concentrations that were not steady state were associated with the largest dosing errors by physicians but did not affect the accuracy of the dosing program. In a second study, we used the dosing program to predict 91 serum concentrations in 31 patients with PHT toxicity after the drug was stopped (initial concentration 26-69 μg/ml). The program predicted serum concentrations with a mean error of 3.49 ± 0.29 μg/ml without significant tendency to overor underpredict. We conclude that this dosing program may aid clinicians by improving dosing accuracy and predicting serum concentrations in patients with PHT toxicity.

KW - Computer

KW - Pharmacoinetics

KW - Phenytoin

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0024596031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024596031&partnerID=8YFLogxK

M3 - Article

C2 - 2728087

AN - SCOPUS:0024596031

VL - 11

SP - 285

EP - 294

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 3

ER -